Sign in

    Thomas Kelliher

    Research Analyst at RBC Capital Markets

    Thomas Kelliher is an Assistant Vice President and Equity Analyst at RBC Capital Markets, specializing in consumer services and finance sector coverage. He has researched companies such as Healthequity Inc. and Privia Health, providing key insights during earnings calls and demonstrating a strong analytical track record. Since joining RBC Capital Markets in 2019, Kelliher has built on previous experience at BMO Capital Markets as a Senior Associate and Senior Analyst, leveraging his MBA from Vanderbilt University to support his expertise. He is professionally credentialed in financial analysis and strategic decision-making and is registered with FINRA, holding requisite securities licenses.

    Thomas Kelliher's questions to HEALTHEQUITY (HQY) leadership

    Thomas Kelliher's questions to HEALTHEQUITY (HQY) leadership • Q3 2025

    Question

    Thomas Kelliher, on for Sean Dodge at RBC Capital Markets, requested an update on the commuter benefits business, its performance relative to pre-pandemic levels, and its outlook for fiscal 2026.

    Answer

    CEO Jon Kessler reported that the commuter business has stabilized at approximately 60-65% of its pre-pandemic revenue. He characterized it as a good business with solid service margins but noted it is not a significant growth driver and is not expected to be a material factor in the company's overall results for fiscal 2026.

    Ask Fintool Equity Research AI

    Thomas Kelliher's questions to Privia Health Group (PRVA) leadership

    Thomas Kelliher's questions to Privia Health Group (PRVA) leadership • Q3 2024

    Question

    Thomas Kelliher, on for Sean Dodge at RBC Capital Markets, asked about the margins of Privia's capitated book of business and any observable utilization trends heading into the fourth quarter.

    Answer

    CEO Parth Mehrotra stated that the small book of business kept under capitation had a positive margin, which was better than expected. He confirmed that headwinds from utilization, Star Scores, and benefit design changes persist, but the company is managing them carefully. He noted that the Q3 results reflect all data received to date and the company hopes to end the year on a positive note for the capitated book.

    Ask Fintool Equity Research AI